Service by

Home Journal Issues Guide for Authors Editorial Board About Aims & Scope Editorial Contact


Original Research Open Access


Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus

Harinika Gullapalli, Savithri Desai.

Abstract
Background: Diabetes mellitus is a heterogeneous chronic metabolic disorder principally characterized by persistent hyperglycemia resulting from defects in insulin action and/or insulin secretion. In course of time, prolonged hyperglycemia and associated metabolic aberrations result in tissue toxicity manifested as accelerated atherosclerosis, renoretinal microangiopathy, and neuropathy leading to a variety of vascular, neurological, and focal complications.

Aim and Objective: The aim of this study is to evaluate the efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients with Type 2 diabetes mellitus.

Materials and Methods: This is a longitudinal interventional study. A total of 60 patients were enrolled in the study. Those patients who were already on metformin 500 mg bid with poor glycemic control were included in the study. These 60 patients were divided into two groups each consisting of 30 patients. Group A patients received glimepiride 1 mg bid and metformin 500 mg bid. Group B patients received vildagliptin 50 mg bid and metformin 500 mg bid. The total period of the study was 3 months.

Results: After 3 months of treatment, both the groups caused a significant decline in blood glucose levels both fasting blood sugar (FBS) as well as postprandial blood sugar (PPBS) levels. There was a significant difference between the two groups in reducing the FBS levels and PPBS. Hemoglobin A1c (HbA1c) was also reduced significantly in both groups at 12 weeks. After 3 months of therapy, there was a reduction in HbA1C in B group. The reduction of HbA1C was not statistically significant between the two groups. Adverse effects were more with metformin and glimepiride group at the end of 3 months therapy. There was a significant difference in the incidence of adverse effects between both the groups.

Conclusions: Vildagliptin and metformin combination provided better efficacy comparable to that of glimepiride and metformin combination and resulted in better adverse effect profile with lower risks of hypoglycemia and weight gain.

Key words: Diabetes Mellitus; Hemoglobin A1C; Fasting Blood Sugar; Postprandial Blood Sugar


 
ARTICLE TOOLS
Abstract
PDF Fulltext
Print this article Print this Article
How to cite this articleHow to cite this article
Export to
Export to
Related Records
 Articles by Harinika Gullapalli
Articles by Savithri Desai
on Google
on Google Scholar
Article Statistics
 Viewed: 72
Downloaded: 31
Cited: 0


How to Cite this Article
Pubmed Style

Gullapalli H, Desai S. Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017


Web Style

Gullapalli H, Desai S. Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. http://www.njppp.com/?mno=283058 [Access: January 22, 2018]. doi:10.5455/njppp.2018.8.1143618112017


AMA (American Medical Association) Style

Gullapalli H, Desai S. Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017



Vancouver/ICMJE Style

Gullapalli H, Desai S. Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017



Harvard Style

Gullapalli, H. & Desai, S. (2018) Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017



Turabian Style

Gullapalli, Harinika, and Savithri Desai. 2018. Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017



Chicago Style

Gullapalli, Harinika, and Savithri Desai. "Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus." doi:10.5455/njppp.2018.8.1143618112017



MLA (The Modern Language Association) Style

Gullapalli, Harinika, and Savithri Desai. "Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus." doi:10.5455/njppp.2018.8.1143618112017



APA (American Psychological Association) Style

Gullapalli, H. & Desai, S. (2018) Comparison of efficacy and safety of metformin and vildagliptin versus metformin and glimepiride in patients of Type 2 diabetes mellitus. doi:10.5455/njppp.2018.8.1143618112017



AUTHOR LOGIN

REVIEWER LOGIN

Indexed In

 

National Journal of Physiology, Pharmacy and Pharmacology is Indexed in -

EMBASE

Index Copernicus  (ICV 2016: 109)

Index Medicus for SEAR

CAB abstract/Global Health

CINAHL

Hinari

Google Scholar

ScopeMed

Ulrich’s International Periodical Directory

Indian Science Abstracts

Open J- Gate

Geneva Foundation for Medical Education and Research

NewJour

PSOAR

InformIndia

EBSCO Publishing Electronic Database

Genamics JournalSeek

ProQuest

Index Scholar

SafetyLit

Chemical Abstracts Service (CAS)

Gale's Health Reference Center

Gale Info Trac

Gale Academic Onefile

Ind Medica

Scirus

Scientific Publication Index

Scientific Resources Database

Recent Science Index

Scholarly Journals Index

Directory of Academic Resources

Elite Scientific Journals Archives

Current Index to Scholarly Journals

Digital Journals Database

Academic Papers Database

Contemporary Research Index

Ayush Web Portal

CiteFactor

 

 

 

 

 

 

Journal Membership

World Association of Medical Editors (WAME), Dallas, Texas, USA

 

Journal Listed in

ICMJE- International Committee of Medical Journal Editors

HIFA 2015 – Healthcare Information for All by 2015, Charlbury, Oxfordshire, UK 

 

 


The articles in this Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.